Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choudhury, A.
Right arrow Articles by Champlin, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choudhury, A.
Right arrow Articles by Champlin, R. E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia

A Choudhury, JL Gajewski, JC Liang, U Popat, DF Claxton, KO Kliche, M Andreeff and RE Champlin

Department of Hematology and Laboratory Medicine, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

The success of adoptive immunotherapy for the treatment of leukemia depends on the generation of T cells that can specifically react with malignant cells. Dendritic cells (DCs) are important antigen-presenting cells in the development of antileukemic T-cell responses. In this study, we generated DCs from peripheral blood cells of patients with chronic myelogenous leukemia (CML). CML cells incubated concurrently with granulocyte-macrophage colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha in vitro developed morphologic and phenotypic characteristics of DCs. Fluorescence in situ hybridization showed the presence of t(9;22) in the nuclei of these cells, indicating that they were leukemic in origin. These cells were potent stimulators of lymphocyte proliferation in specific in vitro assays for DC function. Autologous T cells stimulated with in vitro-generated, leukemic DCs displayed vigorous cytotoxic activity against CML cells but low reactivity to major histocompatability complex-matched normal bone marrow cells. Cytotoxic activity against CML targets was fourfold to sixfold higher using DC-stimulated autologous T cells than with autologous T cells expanded by culture with interleukin-2 alone. DC- stimulated T cells also inhibited growth of CML clonogenic precursors in colony-forming assays in vitro. These results suggest that cytokine- driven in vitro differentiation of CML cells results in generation of DCs with potent T-cell stimulatory function. In vitro-generated DCs can be effectively used as antigen-presenting cells for the ex vivo expansion of antileukemic T cells.

Volume 89, Issue 4, pp. 1133-1142, 02/15/1997
Copyright © 1997 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Griffioen, E. D. van der Meijden, E. H. Slager, M. W. Honders, C. E. Rutten, S. A. P. van Luxemburg-Heijs, P. A. von dem Borne, J. J. van Rood, R. Willemze, and J. H. F. Falkenburg
Identification of phosphatidylinositol 4-kinase type II {beta} as HLA class II-restricted target in graft versus leukemia reactivity
PNAS, March 11, 2008; 105(10): 3837 - 3842.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Terme, C. Borg, F. Guilhot, C. Masurier, C. Flament, E. F. Wagner, S. Caillat-Zucman, A. Bernheim, A. G. Turhan, A. Caignard, et al.
BCR/ABL Promotes Dendritic Cell-Mediated Natural Killer Cell Activation
Cancer Res., July 15, 2005; 65(14): 6409 - 6417.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. W. O'Neill, S. Adams, and N. Bhardwaj
Manipulating dendritic cell biology for the active immunotherapy of cancer
Blood, October 15, 2004; 104(8): 2235 - 2246.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
J. Lee, S. N. Sait, and M. Wetzler
Characterization of dendritic-like cells derived from t(9;22) acute lymphoblastic leukemia blasts
Int. Immunol., October 1, 2004; 16(10): 1377 - 1389.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Cignetti, A. Vallario, I. Roato, P. Circosta, B. Allione, L. Casorzo, P. Ghia, and F. Caligaris-Cappio
Leukemia-Derived Immature Dendritic Cells Differentiate into Functionally Competent Mature Dendritic Cells That Efficiently Stimulate T Cell Responses
J. Immunol., August 15, 2004; 173(4): 2855 - 2865.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Cathcart, J. Pinilla-Ibarz, T. Korontsvit, J. Schwartz, V. Zakhaleva, E. B. Papadopoulos, and D. A. Scheinberg
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
Blood, February 1, 2004; 103(3): 1037 - 1042.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
M. A. Caligiuri, A. Velardi, D. A. Scheinberg, and I. M. Borrello
Immunotherapeutic Approaches for Hematologic Malignancies
Hematology, January 1, 2004; 2004(1): 337 - 353.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. Lindner, M. A. Kharfan-Dabaja, E. Ayala, D. Kolonias, L. M. Carlson, Y. Beazer-Barclay, U. Scherf, J. H. Hnatyszyn, and K. P. Lee
Induced Dendritic Cell Differentiation of Chronic Myeloid Leukemia Blasts Is Associated with Down-Regulation of BCR-ABL
J. Immunol., August 15, 2003; 171(4): 1780 - 1791.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Orsini, A. Guarini, S. Chiaretti, F. R. Mauro, and R. Foa
The Circulating Dendritic Cell Compartment in Patients with Chronic Lymphocytic Leukemia Is Severely Defective and Unable to Stimulate an Effective T-Cell Response
Cancer Res., August 1, 2003; 63(15): 4497 - 4506.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Dong, K. Cwynarski, A. Entwistle, F. Marelli-Berg, F. Dazzi, E. Simpson, J. M. Goldman, J. V. Melo, R. I. Lechler, I. Bellantuono, et al.
Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration
Blood, May 1, 2003; 101(9): 3560 - 3567.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
S.-i. Fujii, K. Shimizu, F. Koji, and F. Kawano
Malignant counterpart of myeloid dendritic cell (DC) belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory potential
J. Leukoc. Biol., January 1, 2003; 73(1): 82 - 90.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
M. Mohty, D. Isnardon, A. Charbonnier, M. Lafage-Pochitaloff, M. Merlin, D. Sainty, D. Olive, and B. Gaugler
Generation of potent Th1 responses from patients with lymphoid malignancies after differentiation of B lymphocytes into dendritic-like cells
Int. Immunol., July 1, 2002; 14(7): 741 - 750.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J.-Y. Sun, R. S. Krouse, S. J. Forman, D. Senitzer, I. Sniecinski, S. Chatterjee, and K. K. Wong Jr.
Immunogenicity of a p210BCR-ABL Fusion Domain Candidate DNA Vaccine Targeted to Dendritic Cells by a Recombinant Adeno-associated Virus Vector in Vitro
Cancer Res., June 1, 2002; 62(11): 3175 - 3183.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Spisek, P. Chevallier, N. Morineau, N. Milpied, H. Avet-Loiseau, J.-L. Harousseau, K. Meflah, and M. Gregoire
Induction of Leukemia-specific Cytotoxic Response by Cross-Presentation of Late-Apoptotic Leukemic Blasts by Autologous Dendritic Cells of Nonleukemic Origin
Cancer Res., May 1, 2002; 62(10): 2861 - 2868.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. B. Schroeijers, A. W. Reurs, G. L. Scheffer, A. G. M. Stam, M. C. de Jong, T. Rustemeyer, E. A. C. Wiemer, T. D. de Gruijl, and R. J. Scheper
Up-Regulation of Drug Resistance-Related Vaults During Dendritic Cell Development
J. Immunol., February 15, 2002; 168(4): 1572 - 1578.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. X. Mahon, X. Delbrel, P. Cony-Makhoul, C. Faberes, J. M. Boiron, C. Barthe, C. Bilhou-Nabera, A. Pigneux, G. Marit, and J. Reiffers
Follow-Up of Complete Cytogenetic Remission in Patients With Chronic Myeloid Leukemia After Cessation of Interferon Alfa
J. Clin. Oncol., January 1, 2002; 20(1): 214 - 220.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. A. Gruber, D. C. Skelton, and D. B. Kohn
Requirement for NK Cells in CD40 Ligand-Mediated Rejection of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Cells
J. Immunol., January 1, 2002; 168(1): 73 - 80.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Mohty, D. Jarrossay, M. Lafage-Pochitaloff, C. Zandotti, F. Briere, X.-N. de Lamballeri, D. Isnardon, D. Sainty, D. Olive, and B. Gaugler
Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment
Blood, December 15, 2001; 98(13): 3750 - 3756.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
K. Kato, Y. Takaue, and H. Wakasugi
T-cell-conditioned medium efficiently induces the maturation and function of human dendritic cells
J. Leukoc. Biol., December 1, 2001; 70(6): 941 - 949.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Montagna, R. Maccario, F. Locatelli, V. Rosti, Y. Yang, P. Farness, A. Moretta, P. Comoli, E. Montini, and A. Vitiello
Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy
Blood, December 1, 2001; 98(12): 3359 - 3366.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. E. Clark, I. A. Dodi, S. C. Hill, J. R. Lill, G. Aubert, A. R. Macintyre, J. Rojas, A. Bourdon, P. L. R. Bonner, L. Wang, et al.
Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein
Blood, November 15, 2001; 98(10): 2887 - 2893.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Yasukawa, H. Ohminami, K. Kojima, T. Hato, A. Hasegawa, T. Takahashi, H. Hirai, and S. Fujita
HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4+ T lymphocytes
Blood, September 1, 2001; 98(5): 1498 - 1505.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
R. F. Storb, R. Champlin, S. R. Riddell, M. Murata, S. Bryant, and E. H. Warren
Non-Myeloablative Transplants for Malignant Disease
Hematology, January 1, 2001; 2001(1): 375 - 391.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. T. Costello, F. Mallet, B. Gaugler, D. Sainty, C. Arnoulet, J.-A. Gastaut, and D. Olive
Human Acute Myeloid Leukemia CD34+/CD38- Progenitor Cells Have Decreased Sensitivity to Chemotherapy and Fas-induced Apoptosis, Reduced Immunogenicity, and Impaired Dendritic Cell Transformation Capacities
Cancer Res., August 1, 2000; 60(16): 4403 - 4411.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
C. Bertazzoli, E. Marchesi, L. Passoni, R. Barni, F. Ravagnani, C. Lombardo, G. M. Corneo, P. Pioltelli, E. Pogliani, and C. Gambacorti-Passerini
Differential Recognition of a BCR/ABL Peptide by Lymphocytes from Normal Donors and Chronic Myeloid Leukemia Patients
Clin. Cancer Res., May 1, 2000; 6(5): 1931 - 1935.
[Abstract] [Full Text]


Home page
Stem CellsHome page
T. Köhler, R. Plettig, W. Wetzstein, M. Schmitz, M. Ritter, B. Mohr, U. Schaekel, G. Ehninger, and M. Bornhäuser
Cytokine-Driven Differentiation of Blasts from Patients with Acute Myelogenous and Lymphoblastic Leukemia into Dendritic Cells
Stem Cells, March 1, 2000; 18(2): 139 - 147.
[Abstract] [Full Text]


Home page
BloodHome page
J. Pinilla-Ibarz, K. Cathcart, T. Korontsvit, S. Soignet, M. Bocchia, J. Caggiano, L. Lai, J. Jimenez, J. Kolitz, and D. A. Scheinberg
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
Blood, March 1, 2000; 95(5): 1781 - 1787.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
M. Brenner, C. Rossig, U. Sili, J. W. Young, and E. Goulmy
Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy
Hematology, January 1, 2000; 2000(1): 356 - 375.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Ohminami, M. Yasukawa, and S. Fujita
HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide
Blood, January 1, 2000; 95(1): 286 - 293.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Langstein, J. Michel, and H. Schwarz
CD137 Induces Proliferation and Endomitosis in Monocytes
Blood, November 1, 1999; 94(9): 3161 - 3168.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Cignetti, E. Bryant, B. Allione, A. Vitale, R. Foa, and M.A. Cheever
CD34+ Acute Myeloid and Lymphoid Leukemic Blasts Can Be Induced to Differentiate Into Dendritic Cells
Blood, September 15, 1999; 94(6): 2048 - 2055.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
F. H. C. Engels, G. K. Koski, I. Bedrosian, S. Xu, S. Luger, P. C. Nowell, P. A. Cohen, and B. J. Czerniecki
Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells
PNAS, August 31, 1999; 96(18): 10332 - 10337.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J.H. F. Falkenburg, A. R. Wafelman, P. Joosten, W. M. Smit, C. A.M. van Bergen, R. Bongaerts, E. Lurvink, M. van der Hoorn, P. Kluck, J. E. Landegent, et al.
Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes
Blood, August 15, 1999; 94(4): 1201 - 1208.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. K. Koski, G. N. Schwartz, D. E. Weng, R. E. Gress, F. H.C. Engels, M. Tsokos, B. J. Czerniecki, and P. A. Cohen
Calcium Ionophore-Treated Myeloid Cells Acquire Many Dendritic Cell Characteristics Independent of Prior Differentiation State, Transformation Status, or Sensitivity to Biologic Agents
Blood, August 15, 1999; 94(4): 1359 - 1371.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
S. Faderl, M. Talpaz, Z. Estrov, and H. M. Kantarjian
Chronic Myelogenous Leukemia: Biology and Therapy
Ann Intern Med, August 3, 1999; 131(3): 207 - 219.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. K. Koski, G. N. Schwartz, D. E. Weng, B. J. Czerniecki, C. Carter, R. E. Gress, and P. A. Cohen
Calcium Mobilization in Human Myeloid Cells Results in Acquisition of Individual Dendritic Cell-Like Characteristics Through Discrete Signaling Pathways
J. Immunol., July 1, 1999; 163(1): 82 - 92.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
Monitoring Treatment and Survival in Chronic Myeloid Leukemia
J. Clin. Oncol., June 1, 1999; 17(6): 1858 - 1858.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
C. L. Sawyers
Chronic Myeloid Leukemia
N. Engl. J. Med., April 29, 1999; 340(17): 1330 - 1340.
[Full Text] [PDF]


Home page
J. Immunol.Home page
D. C. St. Louis, J. B. Woodcock, G. Fransozo, P. J. Blair, L. M. Carlson, M. Murillo, M. R. Wells, A. J. Williams, D. S. Smoot, S. Kaushal, et al.
Evidence for Distinct Intracellular Signaling Pathways in CD34+ Progenitor to Dendritic Cell Differentiation from a Human Cell Line Model
J. Immunol., March 15, 1999; 162(6): 3237 - 3248.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Choudhury, J.C. Liang, E.K. Thomas, L. Flores-Romo, Q.S. Xie, K. Agusala, S. Sutaria, I. Sinha, R.E. Champlin, and D.F. Claxton
Dendritic Cells Derived In Vitro From Acute Myelogenous Leukemia Cells Stimulate Autologous, Antileukemic T-Cell Responses
Blood, February 1, 1999; 93(3): 780 - 786.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Ling, Y.-J. Wen, and S. H. Lim
Prevalence of Antibodies Against Proteins Derived From Leukemia Cells in Patients With Chronic Myeloid Leukemia
Blood, December 15, 1998; 92(12): 4764 - 4770.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Mutis, E. Schrama, C. J.M. Melief, and E. Goulmy
CD80-Transfected Acute Myeloid Leukemia Cells Induce Primary Allogeneic T-Cell Responses Directed at Patient Specific Minor Histocompatibility Antigens and Leukemia-Associated Antigens
Blood, September 1, 1998; 92(5): 1677 - 1684.